Intramuscular 17-hydroxyprogesterone caproate to prevent preterm birth among HIV-infected women in Zambia: study protocol of the IPOP randomized trial

Price, Joan T.; Vwalika, Bellington; Freeman, Bethany L.; Cole, Stephen R.; Mulenga, Helen B.; Winston, Jennifer; Mbewe, Felistas M.; Chomba, Elwyn; Mofenson, Lynne M.; Rouse, Dwight J.; Goldenberg, Robert L.; Stringer, Jeffrey S. A.

Each year, an estimated 15 million babies are born preterm, a global burden borne disproportionately by families in lower-income countries. Maternal HIV infection increases a woman’s risk of delivering prematurely, and antiretroviral therapy (ART) may compound this risk. While prenatal progesterone prophylaxis prevents preterm birth among some high-risk women, it is unknown whether HIV-infected women could benefit from this therapy. We are studying the efficacy of progesterone supplementation to reduce the risk of preterm birth among pregnant women with HIV in Lusaka, Zambia.

The Improving Pregnancy Outcomes with Progesterone (IPOP) study is a Phase III double-masked, placebo-controlled, randomized trial of intramuscular 17-alpha hydroxprogesterone caproate (17P) to prevent preterm birth in HIV-infected women. A total of 800 women will be recruited prior to 24 weeks of gestation and randomly allocated to 17P or placebo administered by weekly intramuscular injection. The primary outcome will be a composite of live birth prior to 37 completed gestational weeks or stillbirth at any gestational age. Secondary outcomes will include very preterm birth (< 34 weeks), extreme preterm birth (< 28 weeks), small for gestational age (<10th centile), low birth weight (< 2500 g), and neonatal outcomes. In secondary analysis, we will assess whether specific HIV-related covariates, including the timing of maternal ART initiation relative to conception, is associated with progesterone’s prophylactic efficacy, if any.

We hypothesize that weekly prenatal 17P will reduce the risk of HIV-related preterm birth. An inexpensive intervention to prevent preterm birth among pregnant women with HIV could have substantial global public health impact.

Trial registration. NCT03297216; September 29, 2017.

Geographic Areas


  • thumnail for 12884_2019_Article_2224.pdf 12884_2019_Article_2224.pdf application/pdf 391 KB Download File

Also Published In

BMC Pregnancy and Childbirth

More About This Work

Academic Units
Obstetrics and Gynecology
Published Here
April 23, 2019


Preterm birth, Progesterone, 17-alpha hydroxyprogesterone caproate, HIV, Antiretroviral therapy, Sub-Saharan Africa